Kyverna Therapeutics KYTX 深 沪
等待开盘 09-22 09:30:00 美东时间
5.80
+0.790
+15.77%
华盛通- 最 高5.99
- 今 开5.16
- 成交量 152.65万股
- 最 低 5.13
- 昨 收 5.01
- 总市值 2.51亿
- 52周最高 7.20
- 市盈率 静 --
- 换手率 3.53%
- 52周最低 1.78
- 委 比 -84.75%
- 总股本 4324.57万
- 历史最高 35.06
- 量 比 3.58
- 振 幅 17.17%
- 历史最低 1.78
- 每 手 1
- 风险率 8.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kyverna Therapeutics To Present Interim Data From Phase 2 Portion Of The KYSA-6 Study Of KYV-101 In Myasthenia Gravis At AANEM 2025
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow upEnrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end
09-16 01:03
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
Kyverna Therapeutics announces Phase 3 trial design for its CAR T therapy KYV-101 targeting myasthenia gravis (MG) and stiff person syndrome (SPS). The trial, aligned with FDA guidelines, aims to demonstrate KYV-101's superiority over standard-of-care treatments. Key endpoints include changes in MG-ADL and QMG scores. KYV-101 has shown potential for durable remission and could be the first FDA-approved therapy for SPS. The Company will host a vir...
08-28 12:00
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
Kyverna Therapeutics' CEO Warner Biddle will participate in three fireside chat sessions at the 2025 Wells Fargo Healthcare Conference (Sept 3), Morgan Stanley 23rd Annual Global Healthcare Conference (Sept 8), and H.C. Wainwright 27th Annual Global Investment Conference (Sept 9). Kyverna, a biopharmaceutical company focused on cell therapies for autoimmune diseases, is advancing its lead CAR T-cell therapy KYV-101 for stiff person syndrome, myas...
08-25 20:02
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy in autoimmune disease.
08-21 03:29
William Blair Initiates Coverage On Kyverna Therapeutics with Outperform Rating
William Blair analyst Sami Corwin initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Outperform rating.
08-20 21:01
Kyverna Therapeutics Q2 EPS $(0.97) Beats $(1.04) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.04) by 7.09 percent. This is a 44.78 percent decrease over losses of $(0.67) per share
08-13 04:21
Kyverna Therapeutics appoints Marc Grasso as CFO
Kyverna Therapeutics (NASDAQ:KYTX) announced on Monday the appointment of Marc Grasso as its chief financial officer (CFO), effective today. Most recently, Grasso served as CFO of Alector, a clinical...
06-30 21:32
美股大行评级 | 潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
05-28 09:04
HC Wainwright & Co. Upgrades Kyverna Therapeutics to Buy, Raises Price Target to $5
HC Wainwright & Co. analyst Mitchell Kapoor upgrades Kyverna Therapeutics (NASDAQ:KYTX) from Neutral to Buy and raises the price target from $4 to $5.
05-27 18:56
快讯 | Kyverna Therapeutics Inc - 预计将在2026年上半年提交Kyv-101的BLA申请
Kyverna Therapeutics Inc - Anticipates Bla Filing for Kyv-101 in 1H 2026
05-14 04:26
